Immunome (NASDAQ:IMNM) CFO Max Rosett Sells 60,000 Shares

Immunome, Inc. (NASDAQ:IMNM) CFO Max Rosett sold 60,000 shares of the stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $18.23, for a total transaction of $1,093,800.00. Following the transaction, the chief financial officer directly owned 54,037 shares of the company’s stock, valued at approximately $985,094.51. This trade represents a 52.61% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Max Rosett also recently made the following trade(s):

• On Thursday, April 2nd, Max Rosett sold 65,000 shares of Immunome stock. The stock was sold at an average price of $21.92, for a total transaction of $1,424,800.00.

Immunome Price Performance

Shares of NASDAQ:IMNM traded up $0.62 during mid-day trading on Wednesday, reaching $18.53. 1,419,601 shares of the company were exchanged, compared to its average volume of 1,357,784. The firm has a market cap of $2.10 billion, a price-to-earnings ratio of -7.79 and a beta of 2.04. The firm’s 50-day simple moving average is $21.62 and its 200 day simple moving average is $21.70. Immunome, Inc. has a 1 year low of $7.96 and a 1 year high of $27.65.

Immunome (NASDAQ:IMNM) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.60) by $0.12. On average, research analysts forecast that Immunome, Inc. will post -2.06 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently commented on IMNM shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Immunome in a research note on Tuesday, April 21st. HC Wainwright reissued a “buy” rating and issued a $40.00 price target on shares of Immunome in a research report on Wednesday, May 13th. Wall Street Zen downgraded shares of Immunome from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. Stephens dropped their price target on shares of Immunome from $33.00 to $30.00 and set an “overweight” rating for the company in a research note on Wednesday, March 4th. Finally, Craig Hallum boosted their price target on shares of Immunome from $33.00 to $36.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Twelve investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.17.

Hedge Funds Weigh In On Immunome

Hedge funds and other institutional investors have recently made changes to their positions in the stock. T. Rowe Price Investment Management Inc. lifted its stake in Immunome by 59.4% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock worth $288,305,000 after acquiring an additional 5,003,824 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of Immunome by 8,659.2% during the 4th quarter. JPMorgan Chase & Co. now owns 2,855,747 shares of the company’s stock worth $61,341,000 after purchasing an additional 2,823,144 shares during the last quarter. Primecap Management Co. CA lifted its position in shares of Immunome by 55.2% during the 4th quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock worth $100,643,000 after purchasing an additional 1,667,432 shares during the last quarter. Balyasny Asset Management L.P. purchased a new stake in shares of Immunome during the 4th quarter worth $30,710,000. Finally, Sofinnova Investments Inc. lifted its position in shares of Immunome by 271.2% during the 4th quarter. Sofinnova Investments Inc. now owns 1,618,477 shares of the company’s stock worth $34,765,000 after purchasing an additional 1,182,426 shares during the last quarter. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.